Cash and cash equivalents, end of period
Roivant Sciences Cash and cash equivalents, end of period increased by 19.4% to $1.49B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 25.6%, from $2.00B to $1.49B. Over 2 years (FY 2022 to FY 2024), Cash and cash equivalents, end of period shows an upward trend with a 26.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher levels indicate strong liquidity and readiness to meet claims, whereas lower levels may signal a need for capital raising or asset liquidation.
Detailed definition
This represents the total liquidity available to the company, including highly liquid assets and cash that may be subjec...
Peer comparison
Insurance companies typically maintain high levels of cash and equivalents to satisfy regulatory liquidity requirements.
other_cash_cash_equivalents_restricted_cash_and_restrict_5675e1Historical Data
| Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $1.42B | $6.69B | $6.55B | $5.69B | $2.03B | $2.00B | $2.73B | $1.25B | $1.25B | $1.49B |
| QoQ Change | — | -15.9% | +369.8% | -2.0% | -13.1% | -64.4% | -1.3% | +36.2% | -54.2% | -0.1% | +19.4% |
| YoY Change | — | — | — | +287.1% | — | +42.6% | -70.1% | -58.4% | -78.1% | -38.5% | -25.6% |
Cash and cash equivalents, end of period at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's cash and cash equivalents, end of period?
- Roivant Sciences (ROIV) reported cash and cash equivalents, end of period of $1.49B in Q4 2025.
- How has Roivant Sciences's cash and cash equivalents, end of period changed year-over-year?
- Roivant Sciences's cash and cash equivalents, end of period decreased by 25.6% year-over-year, from $2.00B to $1.49B.
- What is the long-term trend for Roivant Sciences's cash and cash equivalents, end of period?
- Over 2 years (2022 to 2024), Roivant Sciences's cash and cash equivalents, end of period has grown at a 26.9% compound annual growth rate (CAGR), from $1.69B to $2.73B.
- What does cash and cash equivalents, end of period mean?
- The total amount of cash and highly liquid assets held by the company, including restricted funds.